|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-2.98/-1.26
|
企业价值
33.51M
|
资产负债 |
每股账面净值
-0.71
|
现金流量 |
现金流量率
--
|
损益表 |
收益
4.85M
|
每股收益
0.30
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/18 13:38 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type offemale sexual dysfunction. |